Sunil Solomon, MBBS, PhD, MPH

CRS:

JHU

Role:

Investigators

Position:

Investigator

Sunil Suhas Solomon, MBBS PhD MPH is a Professor of Medicine, in the Division of Infectious Diseases, at the Johns Hopkins University School of Medicine. He is also the Chairman of the YR Gaitonde Medical Educational and Research Foundation, Chennai, India. He completed his medical training at the Sri Ramachandra Medical University in Chennai, India and received a Masters in Public Health and a doctorate in Epidemiology (PhD) from the Johns Hopkins University, USA. Dr. Solomon has been elected into the Phi Beta Kappa honors society for academic excellence and the Delta Omega Public Health honors society. His research is focused on the epidemiology, clinical management and access to HIV and HCV care among vulnerable Indian populations such as people who inject drugs and men who have sex with men. He has over 100 peer-reviewed publication in several highly ranked journals such as the Lancet ID, PLOS Medicine, Lancet HIV, Clinical Infectious Diseases, American Journal of Epidemiology, Addiction and AIDS. In 2015, he was one of the first recipients of the Avenir award, a Director’s award from the National Institutes of Health, USA aimed at identifying individuals who propose high impact research and who show promise of being tomorrow's leaders in the field of drug abuse and HIV.

  • Investigator, Hepatitis TSG (Dec 2015-present)
  • Investigator, A5380
  • Chair, A5360

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More

IMPAACT 2034 - Phase I Study of the Pharmacokinetics,...

This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...

Read More

Identification of Biomarkers That Can Predict Progression...

Purpose: The C-TRIUMPH study has identified 20 household contacts (HHC), who have progressed to active TB from its HHCs cohort...

Read More